Edition:
India

KemPharm Inc (KMPH.OQ)

KMPH.OQ on NASDAQ Stock Exchange Global Market

3.75USD
13 Dec 2017
Change (% chg)

-- (--)
Prev Close
$3.75
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
6,105
52-wk High
$5.35
52-wk Low
$2.45

Select another date:

Fri, Nov 10 2017

BRIEF-KemPharm posts Q3 loss per share $0.68

* KemPharm reports third quarter 2017 results and provides corporate update

BRIEF-KemPharm receives USAN approval for “asalhydromorphone” as nonproprietary name for novel prodrug candidate, KP511

* KemPharm Inc receives USAN approval for “asalhydromorphone” as nonproprietary name for novel prodrug candidate, KP511 Source text for Eikon: Further company coverage:

BRIEF-KemPharm says KP484 allowed to proceed to clinical studies​

* kempharm’s kp484 for the treatment of adhd, an investigational prodrug of methylphenidate, allowed to proceed to clinical studies

BRIEF-KemPharm files IND application for KP484 for the treatment of ADHD

* KemPharm files IND for KP484 for the treatment of ADHD, an investigational prodrug of methylphenidate

BRIEF-Kempharm announces preliminary results from KP415 pharmacokinetic single and multiple dose trial

* Kempharm announces preliminary results from KP415 pharmacokinetic single and multiple dose trial

BRIEF-KemPharm strengthens ADHD prodrug pipeline with development of KP484

* KemPharm strengthens adhd prodrug pipeline with development of KP484, a new, super-extended release adhd methylphenidate product candidate

Select another date: